MedTrace Logo

Diagnostic Accuracy of the "LLIFT", a Novel Non-invasive Biomarker for the Diagnosis of Non Alcoholic Fatty Liver (NAFL) and SteatoHepatitis (NASH) in a Population With High Risk of Metabolic Syndrome"

NCT04616664 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 158

Last updated 2025-12-23

No results posted yet for this study

Summary

The NAFLD is the first cause of liver disease worldwide. The severe form of NAFLD, the NASH progresses to cirrhosis and is responsible of liver mortality. The diagnosis of NASH requires liver biopsy that cannot be used for the screening of the disease.

The broad prevalence of the disease limits also the generalization of liver biopsy even for diagnosis. There is an urgent need for the use and the validation of liver diagnosis biomarkers for the diagnosis of NASH.

Conditions

  • Obesity
  • NASH - Nonalcoholic Steatohepatitis

Sponsors & Collaborators

  • RHU PreciNASH Task 1.4

    collaborator UNKNOWN

  • Région Nord-Pas de Calais, France

    collaborator OTHER

  • University Hospital, Lille

    lead OTHER

Principal Investigators

  • Guillaume Lassailly, MD · University Hospital, Lille

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-16
Primary Completion
2024-01-17
Completion
2024-01-17

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04616664 on ClinicalTrials.gov